This founding indicated nitroxoline suppressed metastasis through the activation of EGR1/circNDRG1/miR-520h/smad7/EMT signaling pathway and circNDRG1 may become a potential biomarker during nitroxoline treatment for bladder cancer. This evidence concerns the gene SMAD7 and urinary bladder cancer.